Drug news
CHMP recommends Xiapex for treatment of Peyronie's disease- Swedish Orphan Biovitrium (SOBI)
On 18 December 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Xiapex from Auxiliam Pharma and SOBI for the treatment of adult men with Peyronie’s disease with a palpable plaque. The marketing authorisation holder for this medicinal product is Swedish Orphan Biovitrum AB (publ).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins